Медицинская литература. Новинки

 

 

 

 

 

 

Оценка эффективности лечения новообразований печени по данным КТ и МРТ: дорожная карта для врача лучевой диагностики

Вы можете загрузить полный текст статьи в формате pdf

В последние годы выбор различных вариантов терапии образований печени становится все шире, отмечается появление новых вариантов химио- и лучевой терапии. В настоящее время растет количество методов локального воздействия на опухоли, таких как радиочастотная абляция, криодеструкция, трансартериальная эмболизация. Клиническая оценка эффекта терапии не дает необходимого результата, поэтому возрастает потребность в адекватной оценке результатов лечения, основанной на данных методов Кт и МРТ В данном литературном обзоре приводятся основные критерии оценки эффективности лечения опухолей различными видами воздействия. Отдельно рассматриваются критерии ВОЗ, RECIST, RECIST 1.1, mRECIST, Choi. Помимо этого обсуждаются новые методики объективизации эффектов терапии, основанные на оценке диффузионно-взвешенных изображений и текстурном анализе.

Ключевые слова:
химиотерапия, радиочастотная абляция, криодеструкция, трансартериальная эмболизация, RECIST, RECIST 1.1, mRECIST, Choi, КТ, МРТ, radiofrequency ablation, cryodestruction, transarterial chemoembolizatioin, RECIST 1.0, RECIST 1.1, mRECIST, Choi, CT, MRI

Литература:
1.Федоров В.Д., Вишневский В.А., Кубышкин B.А., Гаврилин А.В., Икрамов Р.З., Щеголев А.И., Кармазановский Г.Г., Овезов A.M., Кудрявцева Т.Ю., Старикова Ю.В., Сергеева О.И. Радиочастотная абляция злокачественных опухолей печени. Анналы хирургической гепатологии. 2005; 3 (10): 7-16.
2.Афанасьев С. Г., Тузиков С. А. Нерезектабельные опухоли печени (обзор литературы). Сибирский онкологический журнал. 2006; 1 (17): 49-54.
3.WHO Handbook for reporting results of cancer treatment. Geneva, Switzerland: World Health Organisation, 1979. 48 p.
4.Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Glabbeke M.V., Oosterom A.T., Christian M.C., Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors. J. Nat. Cancer. Inst. 2000; 92: 205-216. DOI: 10.1093/jnci/92.3.205.
5.Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47:207-214. DOI: 10.1002/1097-0142(19810101)47: 1207::AID-CNCR2820470134>3.0.CO;2-6.
6.Mazumdar M., Smith A., Schwartz L.H. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J. Clin. Epidemiol. 2004; 57 (4): 358-365. DOI: 10.1016/j.jclinepi.2003.07.015.
7.Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H, Sargen D., Ford R., Dancey J., Arbuck S., Gwyther S.M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45 (2009) 228-247. DOI: 10.1016/j.ejca.2008.10.026.
8.Nishino M., Jagannathan J.P., Ramaiya N.H., Van den Abbeele A.D. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am. J. Roentgenol. 2010; 195 (2): 281-289. DOI: 10.2214/AJR.09.4110.
9.Weng Z., Ertle J., Zheng S., Lauenstein T., Mueller S., Bockisch A., Gerken G., Yang D., Sghlaak J.F. Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma. Oncology Letters. 2013; 6 (6): 1707-1712. DOI: 10.3892/ol.2013.1612.
10.Lencioni R., Llovet J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Seminars in liver disease. Thieme Med. Publ. 2010; 1 (30): 52-60. DOI: http://dx.doi.org/10.1055/s-0030-1247132.ISSN 0272-8087.
11.Galban C.J., Chenevert, T.L., Meyer C.R., Tsien C., Lawrence T.S., Hamstra D.A., Junck L., Sundgren C.P., Johnson D.T., Ross D.J., Rehemtulla A. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nature Med. 2009; 15 (5): 572-576. DOI: 10.1038/nm.1919.
12.Hinrichs J.B., Shin H.O., Kaercher D., Hasdemir D., Murray T., Kaireit T., Lutat C., Vogel A., Meyer B.C., Wacker F.K., Rodt T. Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE. Eur. Radiol. 2016; 26 (10): 3447-3455. DOI: 10.1007/s00330-015-4203-4.
13.Wang Z., Chen R., Duran R., Zhao Y., Yenokyan G., Chapiro J., Schernthaner R., Radaelli A., Lin M., Geschwind J.F. Intraprocedural 3D Quantification of Lipiodol Deposition on Cone-Beam CT Predicts Tumor Response After Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cardiovasc. Intervent. Radiol. 2015; 38 (6): 1548-1556. DOI: 10.1007/s00270-015-1129-9.
14.Miles K.A., Ganeshan B., Hayball M.P. CT texture analysis using the filtration-histogram method: what do the measurements mean? Cancer Imaging. 2013; 13 (3): 400-406. DOI: 10.1102/1470-7330.2013.9045.
15.Park H.J., Kim J.H., Choi S.Y., Lee E.S., Park S.J., Byun J.Y., Choi B.I. Prediction of Therapeutic Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Based on Pretherapeutic Dynamic CT and Textural Findings. Am. J. Roentgenol. 2017: W1-W10. DOI: 10.2214/AJR.16.17398.
16.Cui Y., Zhang X.P., Sun Y.S., Tang L., Shen L. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology. 2008; 248 (3): 894-900. DOI: 10.1148/radiol.2483071407.
17.Marugami N., Tanaka T., Kitano S., Hirohashi S., Nishiofuku H., Takahashi A., Sakaguchi H., Matsuoka M., Otsuji T., Takahama J., Higashiura W., Kichikawa K. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging. Cardiovasc. Intervent. Radiol. 2009; 32 (4): 638-646. DOI: 10.1148/radiol.2483071407.
18.Halappa V.G., Bonekamp S., Corona-Villalobos C.P., Li Z., Mensa M., Reyes D., Eng J., Bhagat N., Pawlik T.M., Geschwind J.F., Kamel I.R. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012; 264 (1): 285-294. DOI: 10.1148/radiol.12112142.
19.Barabasch A., Kraemer N.A., Ciritsis A., Hansen N.L., Lierfeld M., Heinzel A., Trautwein C., Neumann U., Kuhl C.K. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization. Invest. Radiol. 2015; 50 (6): 409-415. DOI: 10.1097/RLI.0000000000000144.
20.Gluskin J.S., Chegai F., Monti S., Squillaci E., Mannelli L. Hepatocellular Carcinoma and Diffusion-Weighted MRI: Detection and Evaluation of Treatment Response. J. Cancer. 2016; 7 (11): 1565-1570. DOI: 10.7150/jca.14582.
21.Koh D.M., Scurr E., Collins D., Kanbe B., Norman A., Leach M.O., Husband J.E. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. Am. J. Roentgenol. 2007; 188 (4): 1001-1008. DOI: 10.2214/AJR.06.0601
22.Zheng D.X., Meng S.C., Liu Q.J., Li C.T., Shang X.D., Zhu Y.S., Bai T.J., Xu S.M. Predicting liver metastasis of gastrointestinal tract cancer by diffusion-weighted imaging of apparent diffusion coefficient values. Wld J. Gastroenterol. 2016; 22 (10): 3031-3037. DOI: 10.3748/wjg.v22.i10.3031.
23.Szurowska E., Nowicki T.K., Izycka-Swieszewska E., Zadrozny D., Markiet K., Studniarek M. Predictive value of apparent diffusion coefficient in evaluation of colorectal carcinoma hepaticmetastases response to radiofrequency ablation. J. Magn. Reson. Imaging. 2013; 38 (5): 1027-1032. DOI: 10.1002/jmri.24089.
24.Mungai F., Pasquinelli F., Mazzoni L.N., Virgili G., Ragozzino A., Quaia E., Morana G., Giovagnoni A., Grazioli L., Colagrande S. Diffusion-weighted magnetic resonance imaging in the prediction and assessment of chemotherapy outcome in liver metastases. Radiol. Med. 2014; 119 (8): 625-633. DOI: 10.1007/s11547-013-0379-3.
25.Yuan Z., Ye X.D., Dong S., Xu L.C., Xu X.Y., Liu S.Y., Xiao X.S. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma. Eur. J. Radiol. 2010; 75 (1): e9-14. DOI: 10.1016/j.ejrad.2009.05.040.
26.Mannelli L., Kim S., Hajdu C.H., Babb J.S., Taouli B. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur. J. Radiol. 2013; 82 (4): 577-582. DOI: 10.1016/j.ejrad.2012.11.026.
27.Nassef M.A. Added value of diffusion weighted MRI in evaluation of treatment response: post radiofrequency ablation for hepatocellular carcinoma. Egypt J. Radiol. Nucl. Med. 2015; 7 (3): 581-590. DOI: 10.1016/j.ejrnm.2015.05.010.
28.Park H.J., Kim S.H., Jang K.M., Lim S., Kang T.W., Park H.C., Choi D. Added value of diffusion-weighted MRI for evaluating viable tumor of hepatocellular carcinomas treatedwith radiotherapy in patients with chronic liver disease. Am. J. Roentgenol. 2014; 202 (1): 92-101. DOI: 10.2214/AJR.12.10212.
29.Yu J.S., Kim J.H., Chung J.J., Kim K.W. Added value of diffusion-weighted imaging in the MRI assessment of perilesional tumor recurrence after hemoembolization of hepatocellular carcinomas. J. Magn. Reson. Imaging. 2009; 30 (1): 153-160. DOI: 10.1002/jmri.21818.
30.Matos A.P., Altun E., Ramalho M., Velloni F., Alobaidy M., Semelka R.C. An overview of imaging techniques for liver metastases management. Expert Rev. Gastroenterol. Hepatol. 2015; 9 (12): 1561-1576. DOI: 10.1586/17474124.2015.1092873.

Treatment Response Evaluation in Hepatic Tumors using CT and MRI: Road Map for Radiologist

The number of available methods for hepatic tumor treatment is steadily increasing. Except traditional surgical resection and systemic chemotherapy there are a lot of effective and increasingly used local methods such as Radiofrequency ablation, cryodestruction, transarterial chemoembolization. Radiologist should be able to assess treatment response and evaluate prognosis. We present review of literature on various systems for hepatic tumor treatment response evaluation. Who, RECIST 1.0, RECIST 1.1, mRECIST and Choi criteria are thoroughly explained in terms of benefits and drawbacks. Also, texture analysis and diffusion-weighted imaging are discussed.

Keywords:
химиотерапия, радиочастотная абляция, криодеструкция, трансартериальная эмболизация, RECIST, RECIST 1.1, mRECIST, Choi, КТ, МРТ, radiofrequency ablation, cryodestruction, transarterial chemoembolizatioin, RECIST 1.0, RECIST 1.1, mRECIST, Choi, CT, MRI